Apyx Medical Corporation (APYX)

Over the past six months, Apyx Medical's stock has experienced notable price movements, including a rise from $3.14 to $4.01. The stock demonstrated significant growth, being up 44.040% in the last three months and 157.380% in the last twelve months as of November 6, 2025. The company reported third-quarter 2025 EPS of $-0.050, surpassing estimates, and announced a proposed public offering of common stock. Earlier in the period, second-quarter results showed a slight revenue decrease, but the company increased its revenue guidance for fiscal year 2025.

The provided search results do not explicitly mention specific demand seasonality for Apyx Medical Corp.'s products and services. The company operates in the cosmetic and hospital surgical markets, which may experience fluctuations based on general economic conditions, healthcare policies, and competitive dynamics. However, no direct information on seasonal demand patterns was found.

Apyx Medical Corp. is an energy technology medical device company specializing in cosmetic and surgical products, operating within the Healthcare sector. Their primary product is Helium Plasma Technology, marketed as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgery. Apyx Medical also develops electrosurgery generators and accessories, and recently launched the AYON Body Contouring System™ in the U.S.

Apyx Medical Corp. is headquartered in Clearwater, Florida, with manufacturing facilities in Clearwater and Sofia, Bulgaria. The company distributes its products directly and through distributors in the United States and internationally, including a recent expansion into the Chinese market.

In the past year, Apyx Medical's Renuvion technology received the 2025 NewBeauty Award for “Best Minimally Invasive Skin Tightener.” The company supported its brand through publications in aesthetic surgery journals and participation in high-profile events. However, a past class action lawsuit alleged off-label use of Apyx's products, which led to increased adverse events and potential regulatory scrutiny.

Apyx Medical Corp. has a diverse ownership structure, with institutional investors holding a substantial stake. Institutional investors control nearly 50% of the outstanding shares. Major institutional shareholders include Nantahala Capital Management, LLC, Archon Capital Management LLC, Royce & Associates Lp, and Vanguard Group Inc. Chuck Royce is noted as owning the most shares of APYX.